NEW YORK (360Dx) – Australian proteomics firm Proteomics International said today it is collaborating with Janssen Research & Development to use its PromarkerD test for diabetic kidney disease in drug development.
Under the terms of the agreement, the companies will evaluate the performance of the PromarkerD test for predicting decline in kidney function and drug response in patients from Janssen's clinical trials. The companies will also look at whether PromarkerD is useful for predicting heart disease.
Financial and other terms of the agreement were not disclosed.
PromarkerD uses mass spectrometry to measure blood-based proteins to predict diabetes patients' risk of developing diabetic kidney disease. Proteomics International launched the test in the Dominican Republic in March 2018 and has since licensed it for commercialization in the US, Mexico, and Spain.